Clinical trial
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
NCT00415051 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00415051 |
|---|---|
| Title | Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine |
| Official title | Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study |
| Acronym | MP-12 |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rift Valley Fever |
| Intervention type | Biological |
| Interventions | RVF MP-12 |
| Enrollment | 20 |
| Start date | Aug 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Dec 22, 2006 |
| Last update posted | Jan 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: